Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.LAB initiates phase II cancer pain trial
The phase II trial is investigating the efficacy and safety of Fentanyl Taifun for the treatment of breakthrough cancer pain, monitoring response at different Fentanyl doses. It is
The phase II trial is investigating the efficacy and safety of Fentanyl Taifun for the treatment of breakthrough cancer pain, monitoring response at different Fentanyl doses. It is
Baraclude (entecavir) is indicated for the treatment of chronic hepatitis B infection in adults with evidence of active viral replication and either evidence of persistent elevations in serum
The bad news for Pfizer was that Ranbaxy has successfully invalidated all claims sought in defense of Pfizer’s Austrian patent covering atorvastatin calcium, the active ingredient in the
The National Institutes of Health (NIH) trial is designed to study antiretroviral therapy (ART) alone versus ART with a therapeutic HIV immunization, Remune, in recently HIV-infected people. The
Chroma will provide the targets and DPI will use its comprehensive compound collection and its proprietary discovery processes and data management tools to identify potential lead compounds or
The primary objective of the phase I clinical study was to evaluate the safety, tolerability and pharmacokinetics of SGS518. The study was conducted among healthy volunteers in two
Data on compounds from Series591 showed that oral administration of several compounds within the series lowered A-Beta42 levels in the plasma and brain of Alzheimer’s disease mouse models.
Depo-subQ provera 104 (medroxyprogesterone acetate injectable suspension) is a long-acting injectable contraception and a new formulation of medroxyprogesterone acetate, which is the same active ingredient as Depo-Provera contraceptive
Dowpharma will manufacture short interfering RNAs (siRNAs), the molecules that induce RNAi, for use in clinical trials. The Dowpharma contract service agreement will provide Alnylam with large quantities
Lannett has now been approved to market 2.5mg and 5mg doses of terbutaline sulfate tablets, making the company the second generic supplier approved to market a copycat version